基因治疗和基因组编辑用于I型糖原储存疾病
Janice Y Chou1, Brian C Mansfield1
1Section on Cellular Differentiation, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States.
Frontiers in molecular medicine
|August 1, 2024
概括
I型糖原储存疾病 (GSD-I) 涉及G6Pase-α或G6PT缺乏,导致葡萄糖平衡性损失. 基因疗法在治疗GSD-I方面表现有前途,临床试验正在进行中.
科学领域:
- 生物化学 生物化学
- 遗传学 遗传学 是一个
- 儿科内分泌学 儿科内分泌学
背景情况:
- I型糖原储存疾病 (GSD-I) 包括GSD-Ia (G6Pase-α缺乏) 和GSD-Ib (G6PT缺乏),这两种都是自体逆向性疾病.
- G6Pase-α/G6PT复合体对葡萄糖平衡至关重要,其功能障碍导致代谢异常和长期健康风险,如癌症和脏疾病.
- 目前的饮食疗法可以控制症状,但不能解决潜在的病理问题,并且治疗患者的并发症仍然存在.
研究的目的:
- 审查GSD-I的病理生理学和基因治疗策略的开发.
- 要突出临床前基因治疗方法的安全性和有效性,用于GSD-Ia和GSD-Ib.
- 讨论正在进行和未来的治疗途径,包括基因增强和基因编辑.
主要方法:
- 对动物模型的审查,以了解GSD-I疾病生物学和病理生理学.
- 复合腺相关病毒 (rAAV) 载体介导基因疗法的临床前评估.
- 对GSD-I基因疗法的正在进行的临床试验的分析.
主要成果:
- 临床前研究表明,RAAV基因治疗对GSD-Ia和GSD-Ib的安全性和有效性.
- 在GSD-Ia中对rAAV介导的基因增强进行的III期临床试验是活跃的 (NCT05139316).
- 一个用于GSD-Ia的mRNA增强的I期临床试验于2022年开始 (NCT05095727).
结论:
- 基因疗法,特别是rAAV介导的方法,代表了GSD-I.安全有效的策略.
- 目前正在进行的临床试验正在推进GSD-I治疗,基因编辑作为未来的可能性.
- 新型遗传技术有可能改善GSD-I患者的长期结果.
相关概念视频
00:59Gene Therapy
25.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.3K
00:49What is Genetic Engineering?
74.0K
Overview
74.0K
01:59CRISPR
50.2K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
50.2K
01:20Inborn Errors of Metabolism
150
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
150
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
02:59Animal Mitochondrial Genetics
7.5K
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
7.5K